Wang Qianqian, Feng Qiang, Zhang Yanmin, Zhou Shaoying, Chen Huimin
Emergency Department, HanDan Central Hospital (East), Handan.
Department of Cardiology, HanDan Central Hospital, Han Dan, China.
Medicine (Baltimore). 2020 Jun 19;99(25):e20729. doi: 10.1097/MD.0000000000020729.
We aimed to investigate the predictive value of microRNA 103 (MIR103) and microRNA 107 (MIR107) for acute respiratory distress syndrome (ARDS) risk, as well as their correlations with overall disease severity and prognosis in sepsis patients.Plasma samples were collected from 196 sepsis patients within 24 hours after enrollment and from 196 healthy individuals (as healthy controls (HCs)) at enrollment. Plasma MIR103 and MIR107 were detected by reverse transcription-quantitative polymerase chain reaction.MIR103 and MIR107 were both decreased in ARDS sepsis patients and non-ARDS sepsis patients compared to HCs, and were reduced in ARDS sepsis patients than non-ARDS sepsis patients. Decreased MIR103 (area under curve (AUC): 0.727, 95% confidence interval (CI): 0.619-0.835) and MIR107 (AUC: 0.694, 95% CI: 0.577-0.811) predicted increased ARDS risk in sepsis patients. Meanwhile, MIR103 and MIR107 were negatively correlated with acute pathologic and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, serum creatinine, C-reactive protein, tumor necrosis factor, interleukin 1β, interleukin 6 and interleukin 8, while positively correlated with albumin in sepsis patients. For prognosis, 28-day mortality was increased in ARDS sepsis patients compared to non-ARDS sepsis patients. Finally, MIR103 and MIR107 were reduced in deaths than survivors of sepsis patients, and decreased MIR103 (AUC: 0.704, 95% CI: 0.626-0.782) as well as MIR107 (AUC: 0.649, 95% CI: 0.569-0.729) predicted increased 28-day mortality risk in sepsis patients.MiR-103 and MIR107 were predictive biomarkers for risks of ARDS and 28-day mortality in sepsis patients, which might improve the management of sepsis.
我们旨在研究微小RNA 103（MIR103）和微小RNA 107（MIR107）对急性呼吸窘迫综合征（ARDS）风险的预测价值，以及它们与脓毒症患者总体疾病严重程度和预后的相关性。在入组后24小时内从196例脓毒症患者中采集血浆样本，并在入组时从196名健康个体（作为健康对照（HCs））中采集血浆样本。通过逆转录定量聚合酶链反应检测血浆MIR103和MIR107。与HCs相比，ARDS脓毒症患者和非ARDS脓毒症患者的MIR103和MIR107均降低，且ARDS脓毒症患者的MIR103和MIR107低于非ARDS脓毒症患者。MIR103降低（曲线下面积（AUC）：0.727，95%置信区间（CI）：0.619 - 0.835）和MIR107降低（AUC：0.694，95%CI：0.577 - 0.811）预测脓毒症患者发生ARDS的风险增加。同时，在脓毒症患者中，MIR103和MIR107与急性病理和慢性健康评估（APACHE）II评分、序贯器官衰竭评估（SOFA）评分、血清肌酐、C反应蛋白、肿瘤坏死因子、白细胞介素1β、白细胞介素6和白细胞介素8呈负相关，而与白蛋白呈正相关。对于预后，ARDS脓毒症患者的28天死亡率高于非ARDS脓毒症患者。最后，脓毒症患者死亡者的MIR103和MIR107低于存活者，MIR103降低（AUC：0.704，95%CI：0.626 - 0.782）以及MIR107降低（AUC：0.649，95%CI：0.569 - 0.729）预测脓毒症患者28天死亡风险增加。MiR - 103和MIR107是脓毒症患者ARDS风险和28天死亡率的预测生物标志物，这可能改善脓毒症的管理。
